Target Validation Information
TTD ID	T48703
Target Name	Toll-like receptor 8 (TLR8)
Type of Target	Clinical trial
Drug Potency against Target	CPG 52364	Drug Info	IC50 = 35 nM
	Resiquimod	Drug Info	EC50 = 1 nM	[1]
Action against Disease Model	CPG 52364	Drug Info	In vitro experiments with DNA, RNA or SLE patient immune complexes stimulated h uMan cells that express h uMan TLR7, TLR8, and/or TLR9 and in vivo experiments with TLR agonist-treated mice have demonstrated that CPG 52364 is a potent and specific inhibitor of murine TLR7 and TLR9 and h uMan TLR7, TLR8, and TLR9. Furthermore, CPG 52364 shows activity in the spontaneous lupus murine model, MRL lpr/lpr mice, as measured by reduction in titers of anti-double-stranded DNA antibody, a common clinical correlate of SLE. CPG 52364 is well tolerated in preclinical animal testing.
References
REF 1	Primary leukocyte screens for innate immune agonists. J Biomol Screen. 2009 Jul;14(6):723-30.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.